GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Starpharma Holdings Ltd (ASX:SPL) » Definitions » Net Interest Income

Starpharma Holdings (ASX:SPL) Net Interest Income : A$1.47 Mil (TTM As of Jun. 2024)


View and export this data going back to 2000. Start your Free Trial

What is Starpharma Holdings Net Interest Income?

Net interest income is the total interest income minus total interest expense. It represents the difference between interest and dividends earned on interestbearing assets and interest paid to depositors and other creditors. Starpharma Holdings's net interest income for the six months ended in Jun. 2024 was A$0.64 Mil. Its net interest income for the trailing twelve months (TTM) ended in Jun. 2024 was A$1.47 Mil.

Starpharma Holdings Net Interest Income Historical Data

The historical data trend for Starpharma Holdings's Net Interest Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Starpharma Holdings Net Interest Income Chart

Starpharma Holdings Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Net Interest Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.52 0.35 0.22 1.27 1.47

Starpharma Holdings Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Net Interest Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.12 0.52 0.75 0.83 0.64

Starpharma Holdings Net Interest Income Calculation

Net interest income is the total interest income minus total interest expense. It represents the difference between interest and dividends earned on interestbearing assets and interest paid to depositors and other creditors.

Net Interest Income for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$1.47 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Starpharma Holdings Net Interest Income Related Terms

Thank you for viewing the detailed overview of Starpharma Holdings's Net Interest Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Starpharma Holdings Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Starpharma Holdings Ltd (ASX:SPL) » Definitions » Net Interest Income
Comparable Companies
ASX:ADO ASX:RAD ASX:CYP ASX:TYP ASX:ATX ASX:NOX ASX:PTX ASX:ILA ASX:NYR ASX:BTC VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX XBRU:UCB ALNY BNTX XKRX:068270 BGNE
Traded in Other Exchanges
SPHRY:USA SPHRF:USA PQ6:Germany
Address
4-6 Southampton Crescent, Abbotsford, Melbourne, VIC, AUS, 3067
Website
https://www.starpharma.com
Starpharma Holdings Ltd is an Australia-based company engaged in the research, development, and commercialization of dendrimer products for pharmaceutical, life science, and other applications. It focuses on the development of VivaGel for the management and prevention of bacterial vaginosis and as a condom coating and VIRALEZE an antiviral nasal spray.

Starpharma Holdings Headlines

No Headlines